Harpoon Therapeutics Strengthens Leadership Team
26 déc. 2023 07h30 HE
|
Harpoon Therapeutics Inc.
James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq:...
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
19 déc. 2023 07h30 HE
|
Harpoon Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
11 déc. 2023 20h15 HE
|
Harpoon Therapeutics Inc.
• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure...
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
09 nov. 2023 16h01 HE
|
Harpoon Therapeutics Inc.
October 2023 financing funds late-stage clinical trials of HPN328 in multiple tumor types Positive interim results from Phase 1/2 trial of T cell engager HPN328 in patients with small cell lung...
Harpoon Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
11 mai 2023 16h30 HE
|
Harpoon Therapeutics
Enrollment for HPN217 (BCMA) and HPN328 (DLL3) remain on track, with data updates and selection of recommended Phase 2 doses for both ongoing clinical programs planned in 2023 Five preclinical...
Harpoon Therapeutics to Participate in the Canaccord Horizons in Oncology Conference
10 avr. 2023 16h05 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., April 10, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
21 nov. 2022 16h59 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
03 nov. 2022 09h09 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
04 oct. 2022 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the...
Harpoon Therapeutics to Participate in Three Upcoming Investor Conferences
01 sept. 2022 07h30 HE
|
Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...